PAI
Palo Alto Investors Portfolio holdings
AUM $470M
1-Year Return
2.57%
This Quarter Return
+10.49%
1 Year Return
+2.57%
3 Year Return
+93.77%
5 Year Return
+190.64%
10 Year Return
+955.02%
AUM
$1.11B
AUM Growth
+$53M
(+5%)
Cap. Flow
-$3.7M
Cap. Flow
% of AUM
-0.33%
Top 10 Holdings %
Top 10 Hldgs %
81.32%
Holding
36
New
7
Increased
8
Reduced
10
Closed
2
Top Buys
| 1 |
Alnylam Pharmaceuticals
ALNY
|
+$29.6M |
| 2 |
Iovance Biotherapeutics
IOVA
|
+$17.1M |
| 3 |
Sarepta Therapeutics
SRPT
|
+$10.3M |
| 4 |
VERV
Verve Therapeutics
VERV
|
+$8.03M |
| 5 |
NVRO
NEVRO CORP.
NVRO
|
+$7.82M |
Top Sells
| 1 |
United Therapeutics
UTHR
|
+$39.6M |
| 2 |
BioMarin Pharmaceuticals
BMRN
|
+$31.8M |
| 3 |
Insmed
INSM
|
+$11.7M |
| 4 |
Amicus Therapeutics
FOLD
|
+$2.13M |
| 5 |
NovoCure
NVCR
|
+$1.47M |
Sector Composition
| 1 | Healthcare | 97.85% |
| 2 | Financials | 2.15% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Insmed
INSM
$30.6B
| $171M | 15.39% |
5,511,721
-377,770
| -6% | -$11.7M |
|
|
2
Amicus Therapeutics
FOLD
$2.47B
| $147M | 13.26% |
10,373,715
-150,307
| -1% | -$2.13M |
|
|
3
BioMarin Pharmaceuticals
BMRN
$10.4B
| $145M | 13.04% |
1,500,749
-330,286
| -18% | -$31.8M |
|
4
Biogen
BIIB
$21.1B
| $98.4M | 8.87% |
380,417
-865
| -0.2% | -$224K |
|
|
5
United Therapeutics
UTHR
$18B
| $87M | 7.84% |
395,784
-180,123
| -31% | -$39.6M |
|
6
Acadia Pharmaceuticals
ACAD
$4.04B
| $75.4M | 6.8% |
2,409,556
+3,763
| +0.2% | +$118K |
|
7
Prothena Corp
PRTA
$439M
| $60.3M | 5.44% |
1,660,057
+2,599
| +0.2% | +$94.4K |
|
|
RVNC
8
DELISTED
Revance Therapeutics, Inc.
RVNC
| $46M | 4.15% |
5,237,284
+8,675
| +0.2% | +$76.3K |
|
9
STAAR Surgical
STAA
$1.35B
| $43M | 3.87% |
1,376,950
+2,128
| +0.2% | +$66.4K |
|
|
10
Alnylam Pharmaceuticals
ALNY
$60.5B
| $29.6M | 2.66% |
+154,437
| New | +$29.6M |
|
11
eHealth
EHTH
$121M
| $23.9M | 2.15% |
2,739,379
| – | – |
|
|
SAGE
12
DELISTED
Sage Therapeutics
SAGE
| $21.5M | 1.94% |
991,525
-14,251
| -1% | -$309K |
|
|
13
Sarepta Therapeutics
SRPT
$1.89B
| $19.4M | 1.75% |
200,905
+106,875
| +114% | +$10.3M |
|
|
14
Iovance Biotherapeutics
IOVA
$832M
| $17.1M | 1.54% |
+2,106,792
| New | +$17.1M |
|
15
Alkermes
ALKS
$4.52B
| $16.7M | 1.51% |
603,400
| – | – |
|
|
NVRO
16
DELISTED
NEVRO CORP.
NVRO
| $16.1M | 1.45% |
750,371
+363,539
| +94% | +$7.82M |
|
17
Align Technology
ALGN
$9.56B
| $15.3M | 1.38% |
55,705
| – | – |
|
18
AnaptysBio
ANAB
$543M
| $14.7M | 1.33% |
686,882
+255,658
| +59% | +$5.48M |
|
19
Syndax Pharmaceuticals
SNDX
$1.3B
| $10.2M | 0.92% |
472,600
| – | – |
|
20
Cytokinetics
CYTK
$5.95B
| $9.33M | 0.84% |
111,717
| – | – |
|
|
21
NovoCure
NVCR
$1.42B
| $8.39M | 0.76% |
561,908
-98,367
| -15% | -$1.47M |
|
|
VERV
22
DELISTED
Verve Therapeutics
VERV
| $8.03M | 0.72% |
+575,817
| New | +$8.03M |
|
23
Gossamer Bio
GOSS
$728M
| $6.53M | 0.59% |
5,958,888
-571,400
| -9% | -$626K |
|
|
BLUE
24
DELISTED
bluebird bio
BLUE
| $4.6M | 0.41% |
+166,667
| New | +$4.6M |
|
25
Karyopharm Therapeutics
KPTI
$54.3M
| $4.41M | 0.4% |
340,146
-38,246
| -10% | -$496K |
|